Enphase at $4.2 Billion: Why Barclays' Target Cuts Matter Now

Why two Barclays target cuts matter more than they look

Barclays' latest cut is small on its own, but it matters because it follows another reduction earlier in the month.

The total cut is modest, but the direction is clear

Barclays had already trimmed Enphase from $35 to $31 earlier this month. Now it has cut that target again, this time to $30 from $31. That one-step change is only about 3%, but combined with the earlier cut, the target is down roughly 14%.

The stock is still trading as if improvement is around the corner

Enphase is still valued at about $4.24 billion, with the stock at $32.33-already above Barclays' new $30 target and its Underweight rating. That creates the central tension. Bulls can still point to Barclays saying the worst is finally behind Enphase. But demand remains the bigger issue, and Barclays has also said European solar demand is still likely mild, with only a modest near-term boost from tensions in the Middle East.

Until Enphase shows clearer proof of stabilization, those target cuts keep the story from being dismissed as routine.

What Barclays is actually revising

The downgrade is less about sentiment and more about a still-soft demand outlook.

Revenue estimates fell because shipments still look weak

Barclays cut its annual revenue forecasts by about 2% in fiscal 2026, 2.5% in fiscal 2027, and 4% in fiscal 2028, mainly because microinverter shipments in the U.S. and rest of world still look softer. Enphase has also already posted negative revenue growth of 1.6% over the last twelve months. Fewer units moving through the channel is the core pressure point.

Europe also does not look like a near-term rescue. Barclays says European solar demand is still likely mild, which limits the case that Europe or geopolitics will quickly offset a sluggish U.S. market.

Cost control helps, but it does not prove a demand rebound

Barclays still expects non-GAAP gross margins are expected to remain in the 45% to 50% range, and it has also trimmed 2026 and 2027 operating expense estimates as Enphase appears to be tracking toward the low end of its $70 million to $75 million of quarterly non-GAAP operating expenses. That suggests management can control the cost base.

Still, cost discipline is not the same as stronger demand. The more positive message from Barclays is that the worst is finally behind Enphase, but the target cut shows the recovery still needs to become more visible in shipments and revenue before the stock is likely to be rerated.